Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 4/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16731359 | 0.79 | SIGMAR1 (0.54) | SIGMAR1HPGDHRH4RXFP1KMT2A | |
| SCHEMBL6844880 | 0.72 | CYP3A4 (0.42) | HPGDTSHRKMT2A | |
| SCHEMBL14146012 | 0.72 | MGLL (0.56) | SIGMAR1HPGDTSHRHSP90AA1 | |
| SCHEMBL12845076 | 0.72 | RXFP1 (0.56) | SIGMAR1HPGDHRH4RXFP1KMT2A | |
| SCHEMBL8569059 | 0.71 | SIGMAR1 (0.58) | SIGMAR1HPGDHRH4RXFP1REN | |
| SCHEMBL12311741 | 0.71 | HPGD (0.65) | SIGMAR1HPGDHRH4TSHR | |
| SCHEMBL19869975 | 0.71 | RXFP1 (0.48) | SIGMAR1HPGDHRH4TSHRRXFP1 | |
| SCHEMBL14174297 | 0.70 | RXFP1 (0.50) | SIGMAR1HRH4RXFP1HSP90AA1 | |
| SCHEMBL5180736 | 0.69 | HTT (0.70) | SIGMAR1HPGDHRH4RXFP1KMT2A | |
| SCHEMBL31520498 | 0.69 | HTT (0.70) | SIGMAR1HPGDHRH4RXFP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | SIGMAR1 1647/4885HPGD 3066/4885HRH4 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.